1. Review recent guideline recommendations for neuromuscular junction blockers. 

2. Review recent guideline recommendations for acute coronary syndrome and hypertension management.

3. Review recent guideline recommendations for pediatric critical asthma. 

4. Discuss recent guideline recommendations as related to patient case(s). 

1. Describe the importance of critical thinking skills in pharmacy practice.

2. Discuss critical thinking in the context of generational changes in learning styles.

3. Identify approaches to enhance critical thinking skills in learners in day-to-day practice and clinical experiences.

4. Recognize common life and personal challenges encountered by pharmacy learners.

5. Describe strategies for mentoring learners to meet individual needs under normal workload or when encountering personal stress and challenges.

1. Describe the history and purpose of the Food and Drug Administration (FDA)’s risk evaluation and mitigation strategies (REMS) programs. 

2. List the adverse effects and monitoring parameters for common REMS medications utilized by children. 

3. Describe mitigation and prevention strategies for common REMS medications utilized by children. 

4. List documentation requirements for REMS drugs, including vigabatrin, ravulizumab/eculizumab, fenfluramine, bosentan, and isotretinoin. 

5. Evaluate your pharmacy’s policies and procedures for handling REMS medications and assess for compliance with REMS audit requirements. 

1. Describe the evolving treatment landscape of multiple sclerosis, including unmet needs that inform consideration of advanced therapies such as HSCT and cellular therapy.

2. Summarize key guideline recommendations and pivotal literature supporting the use of autologous HSCT in relapsing multiple sclerosis and ongoing trials investigating cellular therapy.

3. Review the evidence for the efficacy and safety of HSCT compared to high-efficacy disease-modifying therapies (DMTs) in highly active relapsing-remitting MS.

4. Identify appropriate patient selection criteria and risk-benefit considerations for HSCT and cellular therapy in MS. 

5. Recognize acute and long-term toxicities associated with HSCT, including supportive care needs and monitoring parameters.

1. Define drug stewardship as it relates to optimizing medication use and in patients with kidney disease.

2. Review the safety and efficacy of medications within the context of kidney stewardship.

3. Discuss clinical decision-making skills through case-based scenarios involving patients with kidney disease.

4. Describe key principles and frameworks underlying kidney drug stewardship across the medication-use process.

1. Describe the pathophysiology and symptomatology of myasthenia gravis and its subtypes.

2. Review treatment options for myasthenia gravis, including cholinesterase inhibitors, immunosuppressants, and rapid-response modalities.

3. Discuss current standard of care for selection of agents for acute myasthenia gravis management.

4. Discuss current standard of care for selection of agents for chronic myasthenia gravis management.

5. Explain how novel agents are utilized in the management of myasthenia gravis to create an individualized patient treatment plan. 

6. Describe opportunities to optimize patient access to prescribed therapies, including considerations for formulary integration and patient-assistance plans.

1. Review the recent guidelines for anticoagulation in stroke prevention for atrial fibrillation, treatment of venous thromboembolism and portal vein thrombosis in patients with cirrhosis.

2. Summarize the latest guidelines for the effective and safe reversal of direct oral anticoagulants in clinical practice.

3. Discuss the updated guideline for treatment of venous thromboembolism in pediatric patients.

4. Recognize clinical applications for the latest publications in anticoagulation management into clinical practice.

1. Define complex substance use disorders.

2. Describe the prevention and treatment challenges across the age spectrum. 

3. Summarize treatment options for adult patients with complex substance use disorder, including special populations. 

4. Summarize treatment options for pediatric patients with complex substance use disorder. 

5. Compare SUD treatment for pediatric patients with treatment for adults, including special populations. 

1. Construct a first-hour algorithm to manage patients after smoke inhalation injury.

4. Evaluate common smoke-inhalation injury treatment pitfalls and plan mitigations, including the impact of early interventions on subsequent patient management in the ICU.

5. Design treatments with appropriate antidotes based on clinical presentation, population affected, laboratory findings, and contraindications.

1. Describe the physiological role of GLP1 beyond metabolic regulation and diabetes management.

2. Analyze recent research findings on GLP-1 RA’s effects in behavioral health and neurocognitive disorders, including its potential roles in mood regulation, substance use disorders, appetite control, and cognitive function.

3. Examine current evidence supporting the efficacy of GLP-1 RA therapies for cardiovascular, kidney, and liver conditions.

4. Develop comprehensive treatment plans incorporating GLP-1-RAbased therapies for diverse clinical indications.

1. Summarize current performance and quality metrics for intracerebral hemorrhage (ICH) care. 

2. Assess opportunities for rapid reversal of coagulopathies in anticoagulant-associated ICH. 

3. Choose evidence-based blood pressure targets, agents, and titration strategies in acute ICH.

4. Apply time-sensitive quality metrics for the bundle of care in collaboration with the interprofessional care team. 

1. Discuss the clinical implications of the evolving landscape in vaccination rates among children and pregnant patients in the US.

2. Identify vaccine-preventable diseases most at risk for resurgence due to declining immunization rates.

3. Review management strategies for specific vaccine-preventable diseases in pediatric patients.  

4. Describe some of the alternative therapies families may seek in place of vaccines, despite low data to support their use.

1. ​​Describe risk factors for cardiovascular disease that are common among people living with HIV.​  

2. ​Identify appropriate pharmacological strategies for reducing the risk of cardiometabolic disease in people living with HIV.​ 

3. ​Describe key pharmacotherapeutic considerations for special populations, including pediatrics, adolescents, and geriatrics.​ 

4. ​Identify key strategies to integrate and enhance engagement of HIV care within general primary care settings.​ 

5. ​Recognize practice considerations for the treatment and prevention of HIV in peripartum and maternal care. ​ 

1. Describe the mechanisms of action and clinical benefits of emerging nephrology therapies, including treatments for anemia, IgA nephropathy, and other kidney-related conditions.

2. Analyze the key considerations for integrating new therapies into clinical practice for management of anemia, IgA nephropathy, and other kidney-related conditions, including selection based on patient specific factors and laboratory values, ongoing monitoring requirements, and management of potential adverse effects.

3. Examine the evolving role of pharmacists in implementing new kidney disease treatments while ensuring patient safety and optimizing therapeutic outcomes.

4. Discuss the challenges associated with assessing kidney function and adjusting drug dosages across various stages of kidney disease.

1. Discuss detection methodologies used to determine MRD in pediatric and adult leukemia, including clinical advantages and limitations relevant to practice.

2. Apply MRD results to optimize leukemia treatment decisions, including therapy escalation, deescalation, and sequencing, based on current evidence.

3. Compare MRD-guided treatment approaches across pediatric and adult leukemia populations to support age-appropriate therapy selection and continuity of care.

4. Examine strategies to prevent, monitor, and manage toxicities associated with MRD-driven therapies, including targeted agents, immunotherapies, and hematopoietic stem cell transplantation.

1. Apply current guideline updates in supportive care to assist cancer patients with pain management, cachexia, fatigue, and treatment-related adverse effects.

2. Provide recommendations for the use of cannabis for supportive care during cancer treatment.

3. Assess the pharmacology and pharmacodynamics of the medications used in medical aid in dying (MAiD) practice.

4. Examine the regulatory and operational aspects of MAiD practice for cancer in the United States.

1. Define the core components of AI governance in health systems.

2. Identify where pharmacy leadership should contribute within AI oversight structures.

3. Recognize factors that impact AI trustworthiness for medication use, including safety, monitoring, and bias/equity considerations.

4. Select clinical and operational functions that AI tools can assist with in health-system pharmacy practice.

5. Evaluate how AI adoption should align with organizational goals, policies, and patient safety priorities across varied care settings.

6. Summarize implementation lessons learned to support safe, scalable, interprofessional AI deployment in pharmacy workflow.

1. Using evidence-based tools, evaluate a medication regimen to determine if prescribed medications have an acceptable risk/benefit. 

2. Analyze therapeutic options to use in place of inappropriate medications in older adults. 

3. Design a care plan to deprescribe inappropriate medications for an older adult. 

4. Apply tools to incorporate patients and caregivers in shared decision-making to improve the success of a deprescribing plan. 

1. Identify operational and regulatory challenges associated with 505(b)(2) FDA pathway products, including HCPCS coding complexities, claim denial patterns, biosimilar distinctions, and formulary and reimbursement implications in health system settings.

2. Describe the current payer landscape for biosimilar adoption, including formulary management approaches, coverage variability across insurance plans, and economic considerations supporting institutional decision-making.

3. Describe Clinical Pharmacogenetics Implementation Consortium (CPIC) and FDA pharmacogenomic guidance for high‑impact drug–gene pairs and its application to medication selection in person‑centered care.

4. Discuss integration of pharmacogenomics clinical decision support tools into clinical workflows to prevent adverse drug reactions and optimize therapeutic outcomes.

5. Discuss artificial intelligence (AI) applications in drug information services, including ethical considerations, implementation barriers, and frameworks for responsible AI adoption while maintaining professional standards and patient safety.

1. Review IDSA guidelines, discuss symptoms and differences between uncomplicated, complicated and recurrent UTIs via multiple patient examples.

2. Review UTI treatment options in ambulatory care and older adults as well as length of therapy.

3. Compare therapeutic options for older adults, including discussion of the Beers Criteria, renal considerations, and medications with a high risk of side effects.

4. Review UTI prevention strategies and evidence. Apply in a patient case scenario,

1. ​​Describe the cycle of inflammation, infection, epithelial dysfunction, and lung structure damage that underlies bronchiectasis.​​  

2. Differentiate the various etiologies of non–cystic fibrosis bronchiectasis based on patient specific factors.  

​​​3. Compare the effectiveness of available airway clearance therapies for patients with bronchiectasis.​​  

4. Recommend the appropriate use of brensocatib based on patient specific factors and available evidence from clinical trials.  

5. Formulate an appropriate antimicrobial therapy for P. aeruginosa infections in bronchiectasis patients, including acute exacerbations and chronic suppressive therapy.​​  

6. ​​​​Design a multi-antimicrobial drug therapy plan for patients with nontuberculous mycobacteria infection based on cultures, patient factors, and current guidelines.  

1. Recognize the potential for DPYD variants to cause treatment-limiting and potentially fatal adverse drug reactions.  

2. Identify important considerations when ordering DPYD testing and interpreting DPYD test results.

3. Recognize advocacy efforts and their impact on facilitating policy change for routine DPYD testing.

4. Identify key sources of high-quality, evidence-based Pharmacogenomics information.

5. Identify intrinsic characteristics and medical conditions that impact interpretation of pharmacogenomics results.

6. Discuss evidence-based sources of PGx information to differentiate between appropriate and inappropriate application of pharmacogenomics testing. 

1. Interpret key anti-doping rules relevant to clinical pharmacists.

2. Describe athlete experiences and expectations surrounding anti-doping regulations.

3. Evaluate use of prohibited substances and methods.

4. Show resources available to pharmacists providing care to athlete-patients.

5. Assess how pharmacists can help athletes apply for therapeutic use exemptions.

6. Recommend appropriate supplement use for athletes through evidence-based evaluation of risks and benefits.

1. ​Review newly published ACCP White Paper on Professional Interactions. ​ 

2. ​Describe the evolution of Medical Affairs, highlighting distinct roles and capabilities of clinical pharmacists.​ 

3. ​Discuss the application of ethical and regulatory frameworks to various practice settings and real-world scenarios.​ 

4. ​Outline considerations for ethical, evidence-based collaboration between clinical pharmacist and promotional versus non-promotional industry activities.​ 

5. ​​​Describe the impact of clinical pharmacist-industry partnerships on patient care, population health, and quality improvement initiatives. 

6. ​​​Explain the practice resources available from industry partners to support clinical pharmacists and improve patient care.​​  

1. Evaluate system-based health risks in cardiovascular, skeletal, metabolic, cognitive, and genitourinary domains using knowledge of menopausal hormone fluctuations.

2. Apply evidence-based pharmacologic and nonpharmacologic management strategies, including appropriate use of estrogen, progesterone, and testosterone therapy, to menopausal patient cases.

3. Analyze common misconceptions and safety concerns regarding menopausal hormone therapy and apply current evidence to clinical decision-making.

4. Develop coordinated management and patient education plans for menopausal patients in ambulatory care settings using interprofessional care principles.

1. Describe recent Medicare coverage changes intended to improve medication access.

2. Identify best practices for supporting uninsured individuals, with a focus on addressing the unique needs of immigrant populations.

3. Review the 340B program and how institutional cost savings can be leveraged to expand patient care access.

4. Discuss the use of patient assistance programs to improve medication access across the spectrum of care.

5. Match federal programs, patient assistance programs, and other medication access tools to the populations served, availability in inpatient versus outpatient settings, and associated patient costs.

1. Discuss contributing literature related to pharmacotherapy recommendations in the updated 2025 Hypertension Guidelines.

2. Identify population gaps in the literature utilized in the guidelines.

3. Describe barriers to guideline application in various resource limited settings. 

4. Outline solutions that address barriers in guidelines application.

5. Review evidence-based care plans that address gaps in the guidelines.

1. Assess criteria that may place a patient at high risk of HIV infection.

2. Utilize patient interview skills to conduct a sexual health history and identify HIV risk behaviors.

3. Evaluate patient specific factors that may impact PrEP/PEP therapy selection.

4. Develop a treatment plan for a patient starting PrEP or PEP

5. Apply medication therapy recommendations from the most recent CDC PEP and PrEP guidelines.

1. ​Summarize current inflammatory bowel disease (IBD) treatment goals.​ 

2. ​​​​Differentiate emerging therapeutic options used for inflammatory bowel disease management.​​​  

3. Interpret recent guideline updates and pivotal clinical trial data to inform acute inpatient management of IBD.  

4. ​​​Apply guideline recommendations and clinical trial evidence to outpatient IBD management decisions.​​ 

5. ​​​Analyze treatment positioning and sequencing strategies across IBD therapies based on disease severity, risk stratification, and prior treatment exposure.​​  

6. ​​​Design care plans that incorporate individualized and evidence-based treatment strategies for patients with IBD.​​